New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareHumanin vs PEG-MGF

Humanin vs PEG-MGF

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Humanin
Anabolic & IGF
PEG-MGF
Summary
Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
Half-Life
~4–8 hours (HNG)
~3 days (due to PEGylation)
Admin Route
SubQ
SubQ
Research
Typical Dose
2–8 mg
200–400 mcg
Frequency
3–5 times per week
2–3x per week
Key Benefits
  • Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
  • Inhibits cellular apoptosis
  • Improves insulin sensitivity
  • Reduces cardiovascular risk markers
  • Anti-inflammatory effects
  • Correlates with longevity in centenarian studies
  • Protects against ischemic injury
  • Potential cancer cell apoptosis sensitization
  • Extended half-life (~3 days) vs native MGF (minutes)
  • Systemic muscle satellite cell activation via subcutaneous injection
  • Promotes muscle fiber repair and hypertrophy throughout the body
  • Enhanced recovery from intense training or muscle injury
  • Synergistic with IGF-1 LR3 and growth hormone peptides
  • Useful in sarcopenia, post-injury recovery, and athletic performance
  • Single injection provides multi-day anabolic signaling
Side Effects
  • Injection site irritation
  • Limited human safety data available
  • Water retention and localized swelling
  • Potential hypoglycemia at high doses
  • Theoretical cancer growth risk (growth factor)
  • Injection site reactions
  • +1 more
Stacks With